Summary of project PR002469

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002469. The data can be accessed directly via it's Project DOI: 10.21228/M8H26H This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Project ID: PR002469
Project DOI:doi: 10.21228/M8H26H
Project Title:Higher Plasma Kynurenine to Tryptophan Correlates with Increased Incidence of Mild Cognitive Impairment in Treated Metabolic Syndrome Patients
Project Type:MS quantitative analysis
Project Summary:An increase in cognitive impairment has been observed in metabolic syndrome (MetS) patients. Although alterations in metabolomic profiles have been identified as potential plasma/serum biomarkers of mild cognitive impairment (MCI) and MetS, findings remain inconsistent— likely due to the heterogeneity among MetS patients and the lack of subsequent validation using targeted analysis after initial untargeted analysis. In this study, we validated mass spectrometry-based quantitation methods and quantified amino acids, fatty acids, and tryptophan metabolites in the kynurenine pathway in plasma of ninety-five treated MetS patients with and without MCI assessed by Montreal cognitive assessment. We found that MCI was positively associated with kynurenine to tryptophan ratio (KTR) after the adjustment for age, gender, and BMI, as well as were negatively associated with C20:3 [all-Z-8,11,14] and lysine. One-unit increase in KTR resulted in increased probability of developing MCI by 371%. In contrast, one-unit increases in C20:3 and lysine were associated with decreased odds of developing MCI by 81% and 78%, respectively. Our finding underscores the prominent neuroinflammation, beyond normal aging, in MetS patients, even under ongoing clinical treatment. It also points to the potential of KTR as a risk marker for MCI, offering a valuable complement to the existing cognitive assessments that may be influenced by educational background. In addition, the validated metabolite data is an useful resource for future research. It can facilitate comparisons across different studies, contribute to large-scale analyses, and be used in machine learning models for discovering and validating new biomarkers.
Institute:Mahidol University
Department:Faculty of Medicine Siriraj Hospital
Laboratory:SiCORE-MSB
Last Name:Jariyasopit
First Name:Narumol
Address:2 Prannok, Bangkok, Non-US, 10700, Thailand
Email:narumoljariyasopit@gmail.com
Phone:662-4195507

Summary of all studies in project PR002469

Study IDStudy TitleSpeciesInstituteAnalysis
(* : Contains Untargted data)
Release
Date
VersionSamplesDownload
(* : Contains raw data)
ST003939 Plasma amino acids of treated metabolic syndrome patients with and without mild cognitive impairment Homo sapiens Mahidol University MS 2025-06-25 1 95 Uploaded data (6.7G)*
ST003942 Tryptophan metabolite concentrations in plasma of treated metabolic syndrome patients with and without mild cognitive impairment Homo sapiens Mahidol University MS 2025-06-25 1 95 Uploaded data (47.9M)*
ST003946 Plasma tryptophan concentrations in treated metabolic syndrome patients with and without mild cognitive impairment Homo sapiens Mahidol University MS 2025-06-25 1 95 Uploaded data (51.3M)*
ST003947 Total fatty acids in plasma of treated metabolic syndrome patients with and without mild cognitive impairment Homo sapiens Mahidol University MS 2025-06-25 1 95 Uploaded data (1.9M)*
  logo